You just read:

Merrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 and MM-310

News provided by

Merrimack Pharmaceuticals, Inc.

03 Apr, 2017, 11:30 ET